What Ataluren Treats: Main Uses and Benefits

Ataluren is a specialized treatment focused on addressing the progression of the condition, and it is used for the long-term management of Duchenne Muscular Dystrophy (DMD) in patients who have a confirmed nonsense mutation in the dystrophin gene. This treatment is relevant for easing symptoms related to progressive muscle weakening, and it is considered relevant for patients with this condition in specific age and functional groups. The treatment is applied in addressing the progressive nature of the condition, which is a primary goal in managing this chronic condition.

---

Delaying the Loss of Independent Walking

The principal therapeutic benefit generally relates to assisting with maintaining functional stability and addressing the progressive weakening of lower limb muscles. This helps address symptom clusters that may become intense or disruptive and may assist with maintaining functional stability for a longer period, contributing to easing the overall symptom load associated with the disease's physical progression. The treatment is relevant across domains involving heightened symptom expression, including motor decline, functional ambulation, and supporting critical muscle function.

“The treatment is used to provide supportive relief during periods where functional stability is threatened by muscle weakening.”

---

Supporting Critical Respiratory and Upper Body Function

In addition, the treatment may assist with the long-term support of vital functions. Continuing therapy is relevant for easing the symptoms related to organ-specific functional stress, which supports patients during difficult episodes by easing distress related to breathing capacity. The medication also supports function in the upper limbs, assisting with maintaining functional stability for daily activities.

Quick Fact: Supportive Management for Functional Decline

Who Can and Cannot Use Ataluren?

The eligibility for Ataluren (Translarna) is strictly defined by regulatory bodies, such as the European Medicines Agency (EMA), based on specific patient criteria and absolute exclusions.

Eligibility and Exclusion Criteria

Criteria	Status (Regulatory Basis)
Genetic Requirement	Must have Duchenne Muscular Dystrophy (DMD) caused by a nonsense mutation in the dystrophin gene.
Age Group	Indicated for patients aged 2 years and older. Safety has not been established in children under 2 years or in adults aged 65 and older.
Functional Status	Indication is for ambulatory patients. Patients who lose the ability to walk after starting treatment are not required to discontinue.

Formal Contraindications (Must Not Use)

Ataluren is contraindicated and must not be used in the following populations, as stated in the official prescribing information:

• Patients with known hypersensitivity to ataluren or to any of the product's excipients.
• Patients receiving concomitant use of intravenous aminoglycosides.

Conditional Restrictions

• Renal Function: Use is not recommended for patients with severe renal impairment (eGFR < 30 ml/min) or end-stage renal disease.
• Pregnancy/Lactation: Use is not recommended during pregnancy or while breastfeeding.

Interactions with other medicines and products

The official interaction profile for Ataluren is structured around pharmacokinetic interactions with certain medicines and a specific, clinically significant restriction.

Contraindicated and Avoided Combinations

• Intravenous Aminoglycosides: Co-administration with intravenous aminoglycosides is not permitted. This is due to findings of reduced efficacy of ataluren and an increased risk of nephrotoxicity (decreased renal function) when the products were used together in clinical trials. If intravenous aminoglycoside treatment is necessary, ataluren should be stopped and resumed only two days after the aminoglycoside administration has ended.
• Other Nephrotoxic Medicinal Products: Concomitant use with other medicinal products known to be nephrotoxic is generally not recommended. If such co-administration is unavoidable, careful and continuous monitoring of renal function is advised.

Metabolic and Transport Interactions (Use with Caution)

Ataluren is a substrate of the UGT1A9 enzyme and the BCRP transporter. It is also an inhibitor of UGT1A9 and the organic anion transporters OAT1, OAT3, and OATP1B3. This results in several potential interactions, which require caution:

• Substrates of OAT1, OAT3, and OATP1B3: Co-administration with medicines that are substrates of these transporters (e.g., oseltamivir, acyclovir, ciprofloxacin, valsartan, pravastatin, rosuvastatin) may increase their concentration in the body, requiring careful oversight.
• UGT1A9 Inducers and BCRP Inhibitors: Co-administration with inducers of UGT1A9 (e.g., Mycophenolate Mofetil) or inhibitors of BCRP (e.g., Cyclosporine) should be approached with caution as they may affect ataluren's own plasma levels.
• Corticosteroids: No clinically relevant drug interaction has been found with co-administration of corticosteroids (deflazacort, prednisone, or prednisolone), and no dose adjustments are required. However, blood pressure should be monitored periodically.

Ataluren functions as a ribosomal-targeting agent that modulates the process of translation termination. The primary molecular target is the eukaryotic ribosome, specifically influencing its interaction with premature termination codons (PTCs), which arise from nonsense mutations in messenger RNA (mRNA) transcripts.

The compound interacts with the ribosomal machinery, reducing its sensitivity to the premature stop signal. This interaction promotes the insertion of a near-cognate aminoacyl transfer RNA (tRNA) at the ribosomal A-site, directly opposite the PTC. The insertion of a near-cognate tRNA enables the ribosome to bypass the PTC in a mechanism termed nonsense suppression or readthrough.

This bypass allows the translational machinery to continue polypeptide elongation beyond the premature stop signal, resulting in the synthesis of a full-length protein from the previously truncated mRNA transcript. The intracellular consequence is the restoration of full-length protein levels, counteracting the system-level deficiency caused by the premature termination of translation.

Official Instructions for Ataluren Administration

The use of ataluren is governed by a weight-based, thrice-daily (TID) dosing regimen that is required for long-term administration. The medicine is supplied as granules for oral suspension, available in 125 mg, 250 mg, and 1000 mg sachets, which must be precisely prepared before ingestion.

---

Dosing Schedule and Preparation

The total recommended daily dose is 40 mg/kg of the patient's body weight, which is fractionated across the day. The three daily doses are split in a 1:1:2 ratio: 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. A distinct interval is required between doses, specifically 6 hours between the morning and midday doses, and 12 hours between the evening dose and the next morning's dose.

For administration, the full contents of the sachet(s) must be mixed with at least 30 ml of liquid (e.g., water or juice) or 3 tablespoons of semi-solid food (e.g., yogurt) immediately upon opening. The entire prepared suspension must be consumed to receive the full dose.

---

Administration Conditions and Adjustments

Treatment must be initiated by specialist physicians experienced in managing the condition. The same dosage regimen applies to pediatric patients 2 years and 12 kg. No dose adjustment is required for patients with mild or moderate renal or hepatic impairment. However, treatment initiation is not recommended for previously untreated patients with severe renal impairment (eGFR <30 mL/min).

Official rules for managing missed doses specify that if the delay is less than 3 hours for the morning/midday dose or less than 6 hours for the evening dose, the dose should be taken. If the delay exceeds these limits, the dose must be skipped, and the patient must resume the normal schedule; a double or extra dose is strictly prohibited.

Research Evidence / Overview of Studies

Summary of Mechanism of Action

Research has explored the hypothesis that the drug acts by stimulating the body’s own regulatory pathways. Studies have examined whether this stimulation could potentially support the body's natural processes related to inflammation and tissue repair. This area of investigation remains the subject of ongoing scientific discussion.

---

Key Clinical Trial Findings

A series of Phase 2 and Phase 3 clinical trials have been conducted to evaluate the drug candidate. The primary objective of these trials was to assess tolerability and whether the drug is associated with changes in symptoms over time.

Efficacy and Symptom Management

Research has evaluated whether the drug is associated with a reduction in the frequency of symptoms in participants with the studied condition. Trials reported findings on whether the drug was associated with continued changes in symptom severity.

• Phase 2 Results: Phase 2 trials reported findings on the primary endpoint, which led to the progression to larger Phase 3 studies. These early-stage findings primarily focused on dosage range and tolerability.
• Phase 3 Results: The larger Phase 3 trial program further assessed a range of clinical endpoints. Clinical data evaluated the drug’s relationship with several metrics related to the condition's progression. Research included assessment of overall quality of life metrics.
• Anti-inflammatory Evaluation: Specific studies examined the drug for an anti-inflammatory effect by measuring circulating biomarkers.

Combination Therapy Assessment

The combination treatment was evaluated against monotherapy in a head-to-head study. This trial compared the outcomes of patients receiving the study drug alongside a standard-of-care regimen versus those receiving only the standard-of-care regimen. The evidence profile, based on the studies reviewed, was compared against outcomes for other treatments.

---

Limitations and Future Research

While initial research has provided data on the drug’s profile, its long-term effects continue to be investigated in open-label extensions of the Phase 3 trials. Future research will need to further clarify the exact biological mechanism and the extent of the observed outcomes in broader populations.

Common questions about Ataluren (FAQ)

Q: Is Ataluren a drug that addresses the root cause of the condition it treats?

A: Official documentation describes Ataluren as a protein restoration therapy and readthrough agent. This means it acts at the molecular level by allowing the cell's machinery to bypass a premature stop signal (the nonsense mutation), thereby enabling the production of a full-length, functional protein. This action promotes the synthesis of the full-length protein which is typically deficient due to the genetic error.

Q: Is Ataluren used to treat conditions other than Duchenne muscular dystrophy?

A: The official approved indication for Ataluren is limited to the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mutation in the dystrophin gene. Official regulatory labels do not indicate use for other conditions.

Q: Is Ataluren considered a cure for the condition it treats?

A: Official regulatory documents define Ataluren as a treatment for the condition. The term 'cure' is not defined in the Summary of Product Characteristics (SmPC) or other official drug labels, which classify the drug as a treatment.

Q: Can women or girls with the condition use Ataluren?

A: Regulatory documents primarily define eligibility based on the presence of the specific nonsense mutation and age. The official labels do not specify gender as a restrictive criterion for use, provided the patient meets the necessary genetic and clinical criteria.

Q: Is a rash a possible adverse reaction to Ataluren?

A: Yes. Clinical data reported in regulatory documents indicate that erythematous rash (red rash) has been documented as a common adverse reaction in patients taking Ataluren. Erythematous rash is listed alongside other common side effects.

Q: Are there any over-the-counter medications or supplements that interact with Ataluren?

A: Regulatory documents list specific classes of prescription drugs, such as substrates of the OAT1, OAT3, or OATP1B3 transporters, which should be used with caution due to the risk of increased drug concentrations. Official warnings regarding prescription drugs focus on active ingredients that are substrates of the specified transporters. This information should be reviewed by a physician regarding any concomitant use, including over-the-counter products.

Q: Is the full molecular mechanism of how Ataluren works completely understood by scientists?

A: Regulatory documents describe the drug's action, known as translational readthrough, as promoting the bypass of the premature stop signal. However, these documents also note that the exact biological mechanism and long-term effects remain subjects of ongoing investigation and future research, as is common with many new medicines.

Q: Has research looked into the effect of Ataluren on heart or cardiac function?

A: Yes. Clinical data and long-term registries used for regulatory review have included assessments of cardiac function (e.g., through cardiorespiratory milestones) to observe the effects of Ataluren on disease progression. This is part of the overall safety and efficacy profile assessment.

Q: Are there studies on how Ataluren might affect upper limb muscle function?

A: Yes. Clinical trials and international registries, such as STRIDE, have included standardized assessments to measure the Performance of Upper Limb (PUL) function in patients receiving Ataluren. This data helps evaluate the drug's relationship with a broad range of physical function.

Q: What is the typical duration of treatment with Ataluren?

A: Regulatory documents describe Ataluren as a medicine without a pre-specified maximum duration for treatment in the prescribing information, provided the patient continues to meet the eligibility criteria. It is generally described for ongoing, chronic use as determined by a specialist physician.

Q: Is the absorption of Ataluren affected by having it with or without a meal?

A: Regulatory pharmacokinetics data indicate that the maximum concentration of Ataluren in the blood is typically reached about 1.5 hours after dosing when administered within 30 minutes of a meal. This absorption finding informed the official use conditions described on the label, which require mixing the dose with liquid or semi-solid food.

The official requirements for storing and disposing of ataluren (granules for oral suspension) are specified to maintain product quality and ensure proper environmental disposal.

Storage and Stability

Product State	Temperature Requirement	Stability Limit
Unopened Sachets	Store below 30^circC.	Shelf-life is mathbf4 years.
Prepared Suspension (Refrigerated)	2-8^circC	mathbf24 hours maximum.
Prepared Suspension (Room Temp)	15-30^circC	mathbf3 hours maximum.

Unopened sachets do not require refrigeration and should be kept out of the sight and reach of children. For dose preparation, the full contents of the sachet must be used, and the suspension is best administered immediately.

Disposal Requirements

Regulatory documents strictly mandate that unused or expired ataluren must not be disposed of via wastewater or household waste. Disposal must follow local environmental guidelines, and patients should consult a pharmacist for instructions on how to correctly discard the medicine.